Priser
Platform
Blog
Om os
Download
Neuca
Neuca
Warsaw Stock Exchange
0

Om

Neuca S.A. is a leading healthcare company, primarily focused on the wholesale distribution of pharmaceuticals across Poland. The company's primary function is to ensure the efficient supply of pharmaceutical products to pharmacies, hospitals, and healthcare institutions, thereby playing a crucial role in the healthcare supply chain. Notably, Neuca S.A. also provides additional services such as logistics, marketing, and IT solutions, targeted towards the needs of healthcare providers. In addition to its core distribution business, Neuca S.A. engages in the development and promotion of private label pharmaceutical products, contributing to its diverse portfolio. The company is well-known for its commitment to enhancing pharmaceutical distribution efficiency and supporting the broader healthcare ecosystem. Headquartered in Toruń, Poland, Neuca S.A. is integral to the Polish healthcare market, connecting pharmaceutical manufacturers with the end consumers and ensuring the delivery of vital medicines and health services across the region.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I NEUCA MED ENDAVU: Køb Neuca ($NEU) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Neuca, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.

Information

TickerNEU
Land
Polen
Antal medarbejdere4.445
Hjemmesideneuca.pl
SektorSundhed
IndustriMedicinsk distribution

Udbytter

8,65PLN
'20
10PLN
'21
11,5PLN
'22
13PLN
'23
14,5PLN
'24
16PLN
'25
Ex-udbytte-dato15. jul. 2025
Udbytteafkast2,22%

Analytikerskøn

Baseret på 5 analytikere

Stærkt købKøbHoldSælgStærkt sælg
0%80%20%0%0%